Literature DB >> 7046693

Pharmacology and toxicology of probucol.

F N Marshall.   

Abstract

Mesh：

Substances：

Year:  1982        PMID： 7046693

Source DB:  PubMed          Journal:  Artery        ISSN： 0098-6127


× No keyword cloud information.
  6 in total

1.  Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy.

Authors:  N Kaul; N Siveski-Iliskovic; M Hill; N Khaper; C Seneviratne; P K Singal
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

2.  Probucol inhibits oxidative modification of low density lipoprotein.

Authors:  S Parthasarathy; S G Young; J L Witztum; R C Pittman; D Steinberg
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

3.  Positive correlation between probucol in low density lipoprotein and LDL-lowering.

Authors:  M Shinomiya; K Shirai; Y Saito; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  The oxidative modification of low-density lipoproteins by macrophages.

Authors:  D S Leake; S M Rankin
Journal:  Biochem J       Date:  1990-09-15       Impact factor: 3.857

Review 5.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

6.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.

Authors:  T E Carew; D C Schwenke; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.